A330350 Stock Overview
Engages in the production and sale of pharmaceutical products in South Korea.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
WITHUS PHARMACEUTICAL Co.,LTD. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩7,310.00 |
| 52 Week High | ₩13,680.00 |
| 52 Week Low | ₩6,500.00 |
| Beta | 0.83 |
| 11 Month Change | -5.80% |
| 3 Month Change | -11.50% |
| 1 Year Change | 2.96% |
| 33 Year Change | -50.77% |
| 5 Year Change | n/a |
| Change since IPO | -68.13% |
Recent News & Updates
Recent updates
We Think That There Are Issues Underlying WITHUS PHARMACEUTICALLTD's (KOSDAQ:330350) Earnings
May 25
Here's What Withuspharmaceutical Co.,Ltd.'s (KOSDAQ:330350) Shareholder Ownership Structure Looks Like
Feb 17Calculating The Intrinsic Value Of Withuspharmaceutical Co.,Ltd. (KOSDAQ:330350)
Jan 13
We're Not Counting On WithuspharmaceuticalLtd (KOSDAQ:330350) To Sustain Its Statutory Profitability
Dec 09Shareholder Returns
| A330350 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | -12.9% | -10.6% | -8.1% |
| 1Y | 3.0% | 1.0% | -4.2% |
Return vs Industry: A330350 exceeded the KR Pharmaceuticals industry which returned -4.2% over the past year.
Return vs Market: A330350 exceeded the KR Market which returned -7.9% over the past year.
Price Volatility
| A330350 volatility | |
|---|---|
| A330350 Average Weekly Movement | 5.0% |
| Pharmaceuticals Industry Average Movement | 5.6% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in KR Market | 11.8% |
| 10% least volatile stocks in KR Market | 3.3% |
Stable Share Price: A330350 has not had significant price volatility in the past 3 months.
Volatility Over Time: A330350's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | n/a | n/a | www.withuspharm.com |
WITHUS PHARMACEUTICAL Co.,LTD. engages in the production and sale of pharmaceutical products in South Korea. It offers circulatory agents, endocrine cost medications, osteoporosis treatment products, antithrombotic medicines, central nervous system agents, digestive tract medications, respiratory/skin preparations, musculoskeletal medications, antibiotics, antifungal and antiviral drugs, genitourinary tract medications, psychotropic agents, and other products.
WITHUS PHARMACEUTICAL Co.,LTD. Fundamentals Summary
| A330350 fundamental statistics | |
|---|---|
| Market cap | ₩96.51b |
| Earnings (TTM) | ₩9.19b |
| Revenue (TTM) | ₩90.15b |
10.5x
P/E Ratio1.1x
P/S RatioIs A330350 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A330350 income statement (TTM) | |
|---|---|
| Revenue | ₩90.15b |
| Cost of Revenue | ₩34.09b |
| Gross Profit | ₩56.06b |
| Other Expenses | ₩46.86b |
| Earnings | ₩9.19b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 696.41 |
| Gross Margin | 62.18% |
| Net Profit Margin | 10.20% |
| Debt/Equity Ratio | 20.4% |
How did A330350 perform over the long term?
See historical performance and comparison